• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by RAPT Therapeutics Inc.

    8/14/25 4:34:01 PM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RAPT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    RAPT Therapeutics, Inc.

    (Name of Issuer)


    Common Stock $0.0001 par value per share

    (Title of Class of Securities)


    75382E208

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    75382E208


    1Names of Reporting Persons

    Nantahala Capital Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    951,613.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    951,613.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    951,613.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.75 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    75382E208


    1Names of Reporting Persons

    Wilmot B. Harkey
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    951,613.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    951,613.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    951,613.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.75 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    75382E208


    1Names of Reporting Persons

    Daniel Mack
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    951,613.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    951,613.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    951,613.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.75 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    RAPT Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    561 ECCLES AVENUE SOUTH SAN FRANCISCO, CALIFORNIA, 94080
    Item 2. 
    (a)Name of person filing:

    (1) Nantahala Capital Management, LLC ("Nantahala") (2) Wilmot B. Harkey (3) Daniel Mack (together the "Reporting Persons")
    (b)Address or principal business office or, if none, residence:

    130 Main St. 2nd Floor, New Canaan, Connecticut 06840
    (c)Citizenship:

    (1) Nantahala is a Massachusetts limited liability company. (2) Each of Messrs. Harkey and Mack is a citizen of the United States of America.
    (d)Title of class of securities:

    Common Stock $0.0001 par value per share
    (e)CUSIP No.:

    75382E208
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    As of June 30, 2025, Nantahala may be deemed to be the beneficial owner of 951,613 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares.
    (b)Percent of class:

    As of June 30, 2025, each of the Reporting Persons may be deemed to be the beneficial owner of the following percentage of the total number of Shares outstanding: (1) Nantahala Capital Management, LLC ("Nantahala") : 5.75% (2) Wilmot B. Harkey: 5.75% (3) Daniel Mack: 5.75%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    (1) Nantahala Capital Management, LLC ("Nantahala") : 0 Shares. (2) Wilmot B. Harkey: 0 Shares. (3) Daniel Mack: 0 Shares.

     (ii) Shared power to vote or to direct the vote:

    (1) Nantahala Capital Management, LLC ("Nantahala") : 951,613 Shares. (2) Wilmot B. Harkey: 951,613 Shares. (3) Daniel Mack: 951,613 Shares.

     (iii) Sole power to dispose or to direct the disposition of:

    (1) Nantahala Capital Management, LLC ("Nantahala") : 0 Shares. (2) Wilmot B. Harkey: 0 Shares. (3) Daniel Mack: 0 Shares.

     (iv) Shared power to dispose or to direct the disposition of:

    (1) Nantahala Capital Management, LLC ("Nantahala") : 951,613 Shares. (2) Wilmot B. Harkey: 951,613 Shares. (3) Daniel Mack: 951,613 Shares.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in ss. 240.13d-1(b)(1)(ii)(E). See Item 4(a).
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Nantahala Capital Management, LLC
     
    Signature:/s/ Taki Vasilakis
    Name/Title:Taki Vasilakis / Chief Compliance Officer
    Date:08/14/2025
     
    Wilmot B. Harkey
     
    Signature:/s/ Wilmot B. Harkey
    Name/Title:Wilmot B. Harkey
    Date:08/14/2025
     
    Daniel Mack
     
    Signature:/s/ Daniel Mack
    Name/Title:Daniel Mack
    Date:08/14/2025
    Get the next $RAPT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RAPT

    DatePrice TargetRatingAnalyst
    7/30/2025$14.00Underweight → Neutral
    Analyst
    5/22/2025$6.00Buy
    H.C. Wainwright
    12/26/2024$10.00Neutral → Buy
    H.C. Wainwright
    11/13/2024$7.00 → $2.00Buy → Hold
    Stifel
    11/11/2024$8.00 → $2.00Overweight → Neutral
    Piper Sandler
    11/11/2024Neutral → Underweight
    JP Morgan
    5/14/2024Outperform → Peer Perform
    Wolfe Research
    5/10/2024Buy → Neutral
    Guggenheim
    More analyst ratings

    $RAPT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RAPT Therapeutics Reports Second Quarter 2025 Financial Results

    SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT) ("RAPT" or the "Company"), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the second quarter and six months ended June 30, 2025. "The first half of 2025 has been productive, with several key achievements setting the stage for important catalysts anticipated in the second half of the year," said Brian Wong, President and CEO of RAPT.  "We strengthened our team with the addition of Jessica Savage, an experie

    8/7/25 8:00:00 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RAPT Therapeutics Names Two Industry Veterans to its Board of Directors

    SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Scott Braunstein, M.D., and Ashley Dombkowski, Ph.D., to its board of directors. Dr. Braunstein was appointed as a member of the Audit Committee of the Board and Dr. Dombkowski was appointed as a member of the Nominating and Corporate Governance Committee of the Board. The company's lead product candidate RPT904, is a novel, half-life extended monoclonal antibod

    6/23/25 8:00:00 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split

    SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT) (the "Company"), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that a 1-for-8 reverse stock split of its outstanding shares of common stock will be effective at 11:59 pm Eastern Time June 16, 2025. Following the reverse stock split, the Company's common stock will continue to trade on the Nasdaq Global Market under the symbol "RAPT" with the new CUSIP number 75382E 208. The Company's common stock will begin trading on a rever

    6/13/25 9:00:00 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Dombkowski Ashley L.

    4 - RAPT Therapeutics, Inc. (0001673772) (Issuer)

    6/30/25 8:43:37 PM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Dombkowski Ashley L.

    3 - RAPT Therapeutics, Inc. (0001673772) (Issuer)

    6/30/25 8:41:59 PM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Braunstein Scott

    4 - RAPT Therapeutics, Inc. (0001673772) (Issuer)

    6/24/25 4:25:28 PM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPT
    SEC Filings

    View All

    $RAPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    SEC Form SCHEDULE 13G filed by RAPT Therapeutics Inc.

    SCHEDULE 13G - RAPT Therapeutics, Inc. (0001673772) (Subject)

    8/14/25 4:34:01 PM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by RAPT Therapeutics Inc.

    SCHEDULE 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)

    8/14/25 4:18:11 PM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by RAPT Therapeutics Inc.

    10-Q - RAPT Therapeutics, Inc. (0001673772) (Filer)

    8/7/25 8:07:42 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RAPT Therapeutics upgraded by Analyst with a new price target

    Analyst upgraded RAPT Therapeutics from Underweight to Neutral and set a new price target of $14.00

    7/30/25 7:18:55 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on RAPT Therapeutics with a new price target

    H.C. Wainwright resumed coverage of RAPT Therapeutics with a rating of Buy and set a new price target of $6.00

    5/22/25 8:27:06 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RAPT Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded RAPT Therapeutics from Neutral to Buy and set a new price target of $10.00

    12/26/24 7:14:12 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPT
    Leadership Updates

    Live Leadership Updates

    View All

    RAPT Therapeutics Names Two Industry Veterans to its Board of Directors

    SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Scott Braunstein, M.D., and Ashley Dombkowski, Ph.D., to its board of directors. Dr. Braunstein was appointed as a member of the Audit Committee of the Board and Dr. Dombkowski was appointed as a member of the Nominating and Corporate Governance Committee of the Board. The company's lead product candidate RPT904, is a novel, half-life extended monoclonal antibod

    6/23/25 8:00:00 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development

    SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development to oversee the development of RPT904, a novel, half-life extended monoclonal antibody designed to bind free human immunoglobin E ("IgE"), a key driver of several allergic diseases. RAPT plans to pursue development of RPT904 initially in food allergy and chronic spontaneous urticaria ("CSU").

    4/15/25 8:00:00 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

    SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consultant for the company. "We are pleased to welcome Lori as chair of the board," said Brian Wong, M.D., Ph.D., President and CEO of RAPT. "In the four years that Lori has served as a board membe

    1/6/25 8:00:00 AM ET
    $CTNM
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPT
    Financials

    Live finance-specific insights

    View All

    RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody

    - RAPT obtains worldwide rights excluding China - - Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double digit royalties on future sales - - Jemincare is currently conducting Phase 2 trials in asthma and chronic spontaneous urticaria in China - - RAPT plans to initiate Phase 2b trial in food allergy next year - - RAPT to host a conference call at 8:30 a.m. ET - SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patient

    12/23/24 7:00:00 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon

    - RAPT to host a conference call today at 8:30 am ET - SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that the U.S. Food and Drug Administration (FDA) has verbally notified the company that a clinical hold has been placed on the company's Phase 2b trial of zelnecirnon (RPT193) in atopic dermatitis and its Phase 2a trial in asthma. The company expects to receive a formal clinical hold letter from

    2/20/24 7:30:00 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

    - Confirmed objective response rate (ORR) of 40% in PD-L1 positive (TPS ≥1%) patients with no prior checkpoint inhibitor therapy (CPI) - Median progression-free survival (PFS) of 6.3 months in PD-L1 positive patients at time of data cut off - Confirmed ORR of 50% in patients with PD-L1 high expression (TPS ≥50%) and 38% in patients with PD-L1 low expression (TPS 1-49%) - RAPT to host webcast conference call today at 10:00 am PT SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with s

    11/3/23 12:00:00 PM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by RAPT Therapeutics Inc.

    SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)

    11/14/24 1:22:39 PM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by RAPT Therapeutics Inc.

    SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)

    11/14/24 9:39:56 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by RAPT Therapeutics Inc.

    SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)

    11/12/24 4:59:18 PM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care